Selecting the best frontline treatment in chronic myeloid leukemia - Wikidata - wikimedia - TriplyDB

Selecting the best frontline treatment in chronic myeloid leukemia

Selecting the best frontline treatment in chronic myeloid leukemia

http://www.wikidata.org/entity/Q33764253

about

Tyrosine Kinase Inhibitors Early in the Disease Course: Lessons From Chronic Myelogenous Leukemia Predictive parameters for imatinib failure in patients with chronic myeloid leukemia.Pharmacology and pharmacokinetics of imatinib in pediatric patients.

P2860

Q33806617-3699C72F-4F22-4EBB-AF93-1ADD4692A442 Q47413364-3B37CAAB-8C90-4670-95F3-31ABEFB77023 Q50094239-459375DA-161E-4AEE-BF04-D65D8A79F04E

P2860

Selecting the best frontline treatment in chronic myeloid leukemia

http://www.wikidata.org/entity/Q33764253

description

2015 nî lūn-bûn

@nan

2015 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Selecting the best frontline treatment in chronic myeloid leukemia

@ast

Selecting the best frontline treatment in chronic myeloid leukemia

@en

type

label

Selecting the best frontline treatment in chronic myeloid leukemia

@ast

Selecting the best frontline treatment in chronic myeloid leukemia

@en

prefLabel

Selecting the best frontline treatment in chronic myeloid leukemia

@ast

Selecting the best frontline treatment in chronic myeloid leukemia

@en

P1433

Q33764253-9AB84B9E-07F0-447E-BCF5-F659CE25A5EA

P1476

Q33764253-3997CE46-0861-475A-A81D-16358D8B16EA

P2093

Q33764253-08036366-A147-4737-B6C1-D7208C89CFD6

Q33764253-5B0849A6-7042-46DB-8599-1F8359C25F4A

P2860

Q33764253-0013BB3A-0388-44C1-B770-5B208A4C6800

Q33764253-0022E698-F416-4CF6-8542-4973EBF29460

Q33764253-004406F5-A2AE-40F4-AE58-9CFACB2A088F

Q33764253-037A8AA9-24D2-4E7D-AC34-BA4DF6FBE221

Q33764253-03C5D67A-A149-470C-9CE7-B0DB7B8CF331

Q33764253-060A5735-A6EC-44EA-954B-6D3E9C922F56

Q33764253-0A9F99BF-7007-440B-BB10-8FA335536E72

Q33764253-0C737721-AD9B-45DD-B0ED-23B52D5D7D8E

Q33764253-111370B6-3120-4F89-819B-5CCF2F24F4FC

Q33764253-16BF4E75-5F7D-4838-A987-BA95A3AE12E4

P2888

Q33764253-189B7A30-6D06-44E2-9843-988B0948F474

P304

Q33764253-09CC2986-5D9B-4A5C-AAAF-AB18CFE43EC5

P31

Q33764253-DD863D07-0A6F-4F44-A163-BAFFCC2F27DA

P356

Q33764253-6B19DC1F-6521-40AC-BD97-6E4D4BE2DDFE

P433

Q33764253-B2D1AEC7-3ABD-4A3C-AAF0-7538533093F7

P478

Q33764253-3CEA4591-2A38-4D8A-AC72-92A49B4EE0FA

P50

Q33764253-9E8D3E59-3567-4E35-830E-5473B3D4F26B

P577

Q33764253-B282AE3B-DFC5-4B99-979E-DABC2697346D

P5875

Q33764253-7C740F6C-A1EA-4791-AC5E-CB09D4309122

P6179

Q33764253-9EB50115-87D6-4755-9210-5D3FD295961B

P698

Q33764253-A92D6F8F-B9B2-46C1-AF0F-D6DAF4285EEF

P921

Q33764253-75023701-FC0F-4B78-8A7A-13E853F00794

Q33764253-AEA7D55E-101F-4B5A-8298-E377D2C08DED

P932

Q33764253-09D3E62B-4012-4A1A-834F-D8049C92F066

P356

S11899-015-0254-5

P1433

Current hematologic malignancy reports

P1476

Selecting the best frontline treatment in chronic myeloid leukemia

@en

P2093

Musa Yilmaz

http://www.w3.org/2001/XMLSchema#string

Yasmin Abaza

http://www.w3.org/2001/XMLSchema#string

P2860

Medical Bankruptcy in the United States, 2007: Results of a National Study

Protein phosphatase 2A: a highly regulated family of serine/threonine phosphatases implicated in cell growth and signalling

Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia

AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance

AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL

Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia

Structural resemblances and comparisons of the relative pharmacological properties of imatinib and nilotinib

Overriding imatinib resistance with a novel ABL kinase inhibitor

Risk stratification in the long-QT syndrome.

Results of a prospective phase 2 study combining imatinib mesylate and cytarabine for the treatment of Philadelphia-positive patients with chronic myelogenous leukemia in chronic phase.

P2888

s11899-015-0254-5

P304

145-157

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11899-015-0254-5

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P50

P577

2015-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

275662255

http://www.w3.org/2001/XMLSchema#string

P6179

1042289313

http://www.w3.org/2001/XMLSchema#string

P698

25921387

http://www.w3.org/2001/XMLSchema#string

P921

chronic myeloid leukemia

P932

5459321

http://www.w3.org/2001/XMLSchema#string